OCs and VTE: a practical answer to an old question

In a recent commentary in this journal, Jürgen Dinger1 argued that “the risk of VTE [venous thromboembolism] attributable to COCs [combined oral contraceptives] is a causal effect, primarily dependent on the dose of estrogen" and that the type of progestogen used in the COC probably does not influence this risk. In an editorial in the British Medical Journal that accompanied the publication of the two largest studies to date on this topic, Nick Dunn concluded: “All of the more recent progestogens, possibly except norgestimate, may seem to be at a disadvantage with regard to VTE”.

As VTE is a very rare event, it is unreasonable to expect the answer to the progestogens and VTE question from a randomised controlled trial. We may thus never be able to exclude residual confounding as a possible explanation for the higher VTE rates found with newer progestogens.

Luckily in clinical practice this does not matter much. For OCs, as for any treatment, health professionals should first recommend the safest and most effective treatment, and in the absence of knowledge differences between treatments we should then consider costs.

Most patients requesting a COC request it solely for contraception. Most of these patients will be perfectly happy with a COC containing a second-generation progestogen, usually levonorgestrel (LNG). Dr Dinger does not question that COCs containing LNG are at least as safe and effective as those containing one of the newer progestogens.

The basket of care offered by sexual health services is constantly changing. More than was the case in the past, we promote subdermal and intraterine methods and offer sexually transmitted infection (STI) and HIV screening and manage genitail tract infection. To afford to do this we have to keep costs as low as possible. Where budgets are finite and probably shrinking, the cost of prescribing COCs containing a newer progestogen instead of LNG can be measured in fewer implants or intraterine methods inserted and fewer chlamydia or HIV tests undertaken.

This is as good a reason as any to adhere to Faculty Guidance on First Prescription of Combined Oral Contraception, which states: “A monophasic COC containing 30 µg ethinyl estradiol with norethisterone or levonorgestrel is a suitable first pill (Grade C)”.

Rudiger Pittrof, MSC, MRCOG
Consultant, Enfield Community Services, Reproductive and Sexual Health (RASH), London, UK
E-mail: rudiger.pittrof@enfield.nhs.uk

Ulrike Sauer, MD
Specialist Registrar, Enfield Community Services, Reproductive and Sexual Health (RASH), London, UK

References


Drospirenone and VTE

Following publication in the October 2009 issue of the commentary article regarding the risk of venous thromboembolism (VTE) with combined oral contraceptives (OCs) and subsequent criticisms,1 we would like to share some information regarding prescribing in Zagreb, Croatia of a recently introduced COC, containing 3 mg drospirenone and 30 µg ethinyloestradiol (DRS/PEE) (Yasmin®). We collected data in the city of Zagreb during the period 2004–2008, employing various data sources as follows: data on inpatients from Zagreb; data on the causes of mortality; data on side effects from the Agency for Drugs and Medicinal Products; and data on drug use from Zagreb pharmacies. The total female population under surveillance was approximately 290,000.

In Zagreb, use of COCs in general increased by 31% between 2004 and 2008. This rising tendency was especially pronounced after 2005, when the combination DRS/PEE was introduced. In 2005, DRS/PEE was accounted for 15.4% of the overall utilisation of COCs, which increased to 57.7% in 2008, yielding a 4.4-fold increase. Other COCs classified as fixed combinations of progestogens and estrogens showed a decrease in this period. In common with other COCs, in Zagreb DRS/PEE is issued on private prescription by pharmacists. COCs are usually prescribed by gynaecologists, but may also be prescribed by other specialists.

The number of reported side effects of all drugs of any kind increased by 69.2% (i.e. from 993 in 2005 to 1680 in 2008). Annual trends in the ratio of hospitalisation showed a tendency to increase in all age groups as well as in those potentially exposed to COCs. Data on the significant increase in the use of DRS/PEE and concurrently very low rates of hospitalisation for VTE, which continued to decrease, suggest that there is no correlation between these two parameters.

Marcel Leppée, MD, PhD
Specialist in Public Health, Department of Pharmacoepidemiology, Andrija Stampar Institute of Public Health, Zagreb, Croatia.
E-mail: marcel.leppe@stampa.hr

Mirela Eric, MD, MSc
Plastic Surgeon, Department of Anatomy, School of Medicine, University of Novi Sad, Novi Sad, Serbia

Josip Cillig, MD, PhD
Professor, Department of Pharmacoepidemiology, Andrija Stampar Institute of Public Health, Zagreb, Croatia

Reference


Filshie clip migration and retention

We wish to advise journal readers about an unusual case of Filshie clip migration and retention inside the uterine cavity that to our knowledge has never been reported before.

A 68-year-old woman, with three previous vaginal births, presented with postmenopausal bleeding for 2 weeks. She underwent a laparoscopic Filshie clip sterilisation 25 years ago and had been menopausal for 16 years. An ultrasound scan suggested an endometrial polyp that was confirmed on hysteroscopy. A closed Filshie clip was seen within the uterine cavity and attached to the polyp by flimsy adhesions. The clip was removed along its longitudinal axis with forceps after dilating the ostium. The ostium was not evident except for a small dimple at its expected site. Histology confirmed a benign endometrial polyp.

The clip was lying freely inside the uterine cavity without being expelled. The likely sequence of events could have been a low-grade inflammatory reaction that resulted in incorporation and subsequent burrowing of the clip through the uterine wall into its cavity. Burrowing and migration through the Fallopian tube is also a possibility and could explain the closure of the right ostium by post-inflammatory adhesions.

Laparoscopic sterilisation with Filshie clip remains a popular method of permanent contraception since its introduction by Marcia Filshie and H. F. Filshie in 1961. It is so successful, with a failure rate of 1 in 200.1 The 12.7 mm long and 4 mm wide titanium clip is lined with silicone rubber and is closed round the Fallopian tube by means of an applicator leading to avascular tubal necrosis. The tube eventually divides and the stumps heal leaving two occluded ends.2 The clip usually remains attached to the site of tubal separation and becomes detached when a delay is caused in peritonealisation, the clip may become detached and migrate through tissue planes. This is estimated to occur in 0.6 to 1000 cases.3 Dislodged clips are most commonly found within the peritoneal cavity, typically in the Pouch of Douglas or the paracolic gutters. Migration to the urinary bladder, vagina, rectum and into the perineum leading to an ischiorectal abscess has

References


Reply

To respond to the letter from Des Pittrof and Sauer,1 the two articles published in the British Medical Journal2,3 assessed the risk of venous thromboembolism (VTE) associated with the use of oral contraceptives (OCs), and in particular the role of the type of progestogen. My commentary addressed the methodological strengths and weaknesses of these two studies. It did not seek to question the findings of the two RCTs for OCs and VTE but could well differ with respect to others – for example, of arterial thromboembolic events such as acute myocardial infarction and stroke.

In addition, I would like to point out that the type of progestogen used in the COC is different with regard to a number of pharmacological characteristics, such as anti-androgenic and anti-mineralocorticoid properties. While manufacturers’ sales organizations have been trying to emphasise even overemphasise differences in the pharmacological profiles of progestogens, that does not mean that these differences are negligible in clinical practice.

At a time when it is becoming increasingly difficult to finance health care, cost-conscious use of pharmaceutical products should not be a taboo topic – especially if these products are not paid for by the patients or users themselves. This applies, for example, to OCs in the UK – in contrast to the vast majority of other countries. Here I would agree with Drs Pittrof and Sauer. However, I am also explicitly in favour of discussing and critically examining safety concerns that are published about certain groups of OCs yet that are of debatable scientific merit – independently of the price sensitive on these products. Any other position on this matter would be scientifically questionable as well as irresponsible. The debate surrounding second- and third-generation OCs has made us all aware of how easily questions about safety can become a fossil ‘‘afflicted ‘‘pill scare’’ that does not remain focused on a certain group of products but instead leads to an overall drop in OC use. That can, in turn, lead to increased abortion rates, and does a disservice to women who do not wish to become pregnant.

Jürgen Dinger, MD, PhD
Director, Berlin Centre for Epidemiology and Health Research, Berlin, Germany.
E-mail: dinger@czg-berlin.de

References

been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported. Extrusion through the anterior abdominal wall is also known. These migration events have been reported.

Another example is Clameleon® (azithromycin), now the first oral antibiotic in the UK to be available without a prescription to asymptomatic individuals with a positive chlamydia test and their partners.

This year the Committee of Advertising Practice (CAP), which is concerned with regulating advertising in the UK, carried out a review of its code that involved a public consultation. The outcome of the CAP code review could facilitate the promotion of sexual health services in future. Some people do not support the advertisement of sexual health services, and there is a small chance the outcome may be different from that anticipated. However, in this regard, one study on direct to consumer advertising (DTCA) of medicinal products showed:

- It increases consumer awareness
- It motivates consumers to seek additional information from health professionals and other sources
- It aids patient-doctor discussions
- It even motivates the pursuance of lifestyle changes in place of POMs.

In addition, a systematic review of the impact of DTCA from the consumer’s perspective concluded that:

- DTCA can facilitate the process completion with older consumers (in this case, it will be compliance with a contraceptive method)
- It appears to increase the demand for treatments and medicines (hopefully long-acting reversible contraception, in this case).

This evidence shows that raising awareness through advertising has the potential to be successful and could help combat the country’s teenage pregnancy and sexually transmitted infection rates.

Hannat Akintomide, MBBS, FSRH
Specialty Doctor, Camden Contraceptive Services, Margaret Pyke Centre, London, UK
E-mail: hannat.akintomide@camdenpct.nhs.uk

References

What’s in a name?
In the January 2004 issue of this journal, Toni Belfield criticised the continuing use of the term ‘coil’ for intrauterine devices (IUDs). Six years later, as one of the largest distributors of intrauterine contraception in the UK, I share her concerns.

Toni made the point that much of our language has changed over time (e.g. ‘automobile’ to ‘car’) and therefore the change from ‘coil’ to ‘IUD’ should not be difficult. Unfortunately, I feel she missed one crucial point and that is that we are all intrinsically, linguistically lazy. In fact, all the examples Toni gave of changing terminology proved this, in that all the newer terms had fewer syllables than those they were replacing (e.g. ‘long-playing record’ to ‘CD’ or ‘album’). In contrast, ‘coil’ has only one syllable, but ‘IUD’ has three and that, I believe, is why the majority of us still use ‘coil’ in preference.

‘Coil’ is a hard, cold, slightly sinister term, reminiscent of reptilian features. My suggested alternative, on the other hand, is monosyllabic, soft, warm and friendly and may even endow the humble IUD with a fluffy-soft-oozing-blissful-appearance. I think we should call IUDs ‘Tees’ (or ‘Tease’?).

The intrauterine system (IUS), of course, would be ‘Hormonal Tease’. (Come to think of it, I went out of fashion quite a while ago.)

After a few years of colloquial use, I anticipate male pulses racing when they hear the phrase ‘Teese’s ready’ but perhaps experiencing slight anxiety at the cautionary ‘Hurry up, Tees’s getting cold’. ‘Tee dances’ will take on a whole new lease of life, not to mention ‘Tee parties’ and ‘Tee for two’.

So that is my New Year Resolution – I shall not use the term ‘coil’ ever again. It’s ‘Tee’ for me, and I hope all readers of this journal will follow suit.

Anyway, anyone for ‘Tee’?

Colin G Parker
Manager, Clinic Services, Daruwin PLC, South Harrow, UK. E-mail: c.parker@darwin.co.uk

References
1. Belfield T. What we say and how we say it... J Fam Plann Reprod Health Care 2004; 30: 11.

Reply
This truly is a no-brainer. I recall at the term ‘coil’ and I definitely wheeze at the term “Tees”! Why do we have such a problem with using correct and accessible sexual health language? Contraceptive methods have evolved hugely over time; we now have safer, more effective methods, but our language around contraception remains archaic, unclear and confusing. Colin Parker suggests we are intrinsically lazily using terms that are getting cold! Actually what we do is make assumptions about our clients’ abilities and understanding; use terminology we have always used and I definitely wheeze at the term “Tees”!

I even persuade people to use the term ‘IUD’ as the abbreviation ‘Tees’ is prone to be easily misunderstood! As a medical student, I certainly find the term ‘IUD’ much easier to say, understand and therefore the change from ‘coil’ to ‘IUD’ makes much more sense. Why would we use the term ‘Tees’ when the abbreviation ‘IUD’ is much easier to say and understand?

Toni Belfield, FRSPH, Hon FFSPH
Specialist in Sexual Health Information, UK.
E-mail: Toni-b@tiscalo.co.uk

Reference